Minimus Spine is the manufacturer of the Triojection® System, which offers an alternative to surgery for patients with leg pain associated with a disc herniation. Minimus Spine reports today that it has had a key patent issue in the United States. Patent 8,961,471 covers aspects of the Triojection® syringe cartridge that maintain sterility of the syringe while the device is being processed within the Triojection® console. Triojection® is the only system in the world with the ability to produce and measure ozone in a sterile syringe. The system is CE Marked in Europe and first cases were performed last year.
“Triojection® is an extremely differentiated product in the fast growing interventional spine market. This patent further strengthens our portfolio of intellectual property, which will be important as others and are drawn into this space. The subject matter included in this patent issued in Europe and Australia last year and we are pleased to be granted similar protection in the United States.” said David Hooper, Ph.D., Minimus Spine’s President and Chief Executive Officer. “Feedback on our initial patients treated last year has been extremely positive and we are steadily progressing on our European post-market study. That study will randomize patients to Triojection® or surgical discectomy and compare the outcomes and costs associated with each procedure. This effort continues to be our primary focus and enrollment is expected to commence in the second quarter.” added Dr. Hooper.
